Neurocrine Biosciences (NBIX) EBT (2010 - 2026)

Neurocrine Biosciences has reported EBT for 17 years, with the latest figure at $246.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 1578.91% year-over-year to $246.8 million; the trailing twelve-month figure through Mar 2026 stood at $937.5 million (up 101.09% YoY), and the FY2025 full-year result was $705.4 million, up 45.14% from the prior year.
• EBT for Q1 2026 stood at $246.8 million, up from $239.4 million in the prior quarter.
• The five-year high for EBT was $291.8 million in Q3 2025, with the low at -$103.3 million in Q1 2023.
• Historically, EBT has averaged $116.7 million across 5 years, with a median of $117.9 million in 2022.
• Annual changes were most pronounced in 2023 — EBT sank 582.71% — and 2026, when it soared 1578.91%.
• Neurocrine Biosciences' EBT stood at $117.9 million in 2022, then surged by 68.11% to $198.2 million in 2023, then fell by 17.96% to $162.6 million in 2024, then jumped by 47.23% to $239.4 million in 2025, then climbed by 3.09% to $246.8 million in 2026.
• The last three EBT figures came in at $246.8 million (Q1 2026), $239.4 million (Q4 2025), and $291.8 million (Q3 2025), per Business Quant data.